Evidence Table J2. CONTINUOUS outcomes for class ANTI-BACTERIAL (ORAL)/RETINOID (TOPICAL)

Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

Tretinoin + emollient + 

tetracycline

Tetracycline + sulfur/salicylic 

acid + polyethyle

J.01.03

323 Comedones change (%)

Between P-value: Tret/Tet vs Tret/BP .05 ; 

Tret/BP vs Tet/Sul NS.

Short (4) Percent change: -25 Percent change: -3

Parallel Mild/mod/sev

È N=122

Papules+pustules change (%)

Between P-value: Tret/Tet vs Tret/BP NS ; 

Tret/BP vs Tet/Sul NS.

Short (4) Percent change: -42 Percent change: -40

Total lesions change (%)

Between P-value: Tret/Tet vs Tret/BP .05 ; 

Tret/BP vs Tet/Sul NS.

Short (4) Percent change: -30 (30.) Percent change: -15 

(40.)

Comedones change (%) Mid (12) Percent change: -63 Percent change: -40

Comedones change (%)

Between P-value: Tret/Tet vs Tret/BP .001 ; 

Tret/BP vs Tet/Sul NS.

Mid (12) Percent change: -65 Percent change: -40

Inflammatory change (%)

Between P-value: Tret/Tet vs Tret/BP .05 ; 

Tret/BP vs Tet/Sul .05.

Mid (12) Percent change: -75 Percent change: -50

Total lesions change (%)

Between P-value: Tret/Tet vs Tret/BP .01 ; 

Tret/BP vs Tet/Sul NS.

Mid (12) Percent change: -68 (30.) Percent change: -45 

(40.)

Dryness

Between P-value: Tret/Tet vs Tret/BP .001 ; 

Tret/BP vs Tet/Sul NS.

Long (16 Measure: 0 Measure: 1

Erythema

Between P-value: Tret/Tet vs Tret/BP NS ; 

Tret/BP vs Tet/Sul NS.

Long (16 Measure: 0 Measure: 0

Inflammatory change (%)

Between P-value: Tret/Tet vs Tret/BP .05 ; 

Tret/BP vs Tet/Sul NS.

Long (16 Percent change: -75 Percent change: -53

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable J CONTINUOUS: Page 1 of 2

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

323 Oiliness

Between P-value: Tret/Tet vs Tret/BP NS ; 

Tret/BP vs Tet/Sul NS.

Long (16 Measure: 0 Measure: 0

Parallel Mild/mod/sev

È N=122

Peeling Long (16 Measure: 0 Measure: 1

Total lesions change (%)

Between P-value: Tret/Tet vs Tret/BP .001 ; 

Tret/BP vs Tet/Sul NS.

Long (16 Percent change: -70 (40.) Percent change: -45 

(40.)

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable J CONTINUOUS: Page 2 of 2

ÈÍ